Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

BioNTech SE (BNTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow BioNTech's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
158.72 +1.23    +0.78%
15:02:47 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US09075V1026 
CUSIP:  09075V102
  • Volume: 1,344,874
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 151.08 - 162.82
BioNTech 158.72 +1.23 +0.78%
InvestingPro Earnings Insights
Latest Release

May 09, 2022

EPS / Forecast

14.24 / 9.16

Revenue / Forecast

6.37B / 4.34B

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Nov 07, 2022 09/2022 -- /  6.24 -- /  3.5B
Aug 08, 2022 06/2022 -- /  7.25 -- /  4.15B
May 09, 2022 03/2022 14.24 /  9.16 6.37B /  4.34B
Mar 30, 2022 12/2021 12.18 /  7.44 5.53B /  3.92B
Nov 09, 2021 09/2021 12.35 /  10.54 6.09B /  5.1B
Aug 09, 2021 06/2021 10.77 /  7.54 5.31B /  3.25B
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View upcoming earnings forecasts and in-depth analysis of company forecasts.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BNTX Comments

Write your thoughts about BioNTech SE
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
gowtham kotha
gowtham kotha Jun 20, 2022 4:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No direction yet
Rob Roo
Rob Roo May 23, 2022 2:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀🔆Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose.
Alp Gunaydin
Alp Gunaydin May 10, 2022 5:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Covid is done, just like this stock. No movea will occur Until they produce something from their pipeline
Alper Drn
Alper Drn May 10, 2022 5:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Coming soon I believe..
Rob Roo
Rob Roo Apr 28, 2022 12:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀 Great entry point for Therapeutics ready to release from the huge pipeline!
We Fi
We Fi Apr 27, 2022 12:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
covid globe it is best isn't it?
Rob Roo
Rob Roo Apr 27, 2022 11:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀 BioNTech submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age (also referred to as children ages 5 through <12).The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose approximately 6 months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10-µg two-dose primary series, which was authorized under EUA for this age group in October 2021. Data from this study demonstrated a strong immune response in this age group following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine with no new safety signals.
Rob Roo
Rob Roo Apr 26, 2022 1:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BNTX will announce its financial results for the first quarter 2022 on Monday, May 9th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2022.
Rob Roo
Rob Roo Apr 25, 2022 5:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New variants will keep BNTX consistently developing, keeping the public guarded, and deriving steady revenue upsurges...
marian dodu
marian dodu Apr 20, 2022 5:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
rrrrright.....
Vlas Dacian
Vlas Dacian Apr 19, 2022 9:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bellow 100$ in summer
Carlos GV
Carlos GV Apr 19, 2022 9:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sure sure... take that pill and RIP!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email